Corpus Intelligence IC Memo — MYMICHIGAN MEDICAL CENTER GLADWIN 2026-04-27 05:14 UTC
IC Memo — MYMICHIGAN MEDICAL CENTER GLADWIN
Investment Committee Memorandum | MI | 25 beds | Grade C | EBITDA uplift $3.4M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 231325

MYMICHIGAN MEDICAL CENTER GLADWIN

LOCATIONnan, MI·BEDS25·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

MYMICHIGAN MEDICAL CENTER GLADWIN is a 25-bed rural/critical access in nan, MI with $45.8M in net patient revenue and a 8.4% operating margin. The hospital serves a payer mix of 43.2% Medicare, 0.3% Medicaid, and 56.6% commercial.

Thesis: Turnaround. Our ML models identify $3.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.4% to 15.8% (+736bps).

Net Revenue HCRIS$45.8M
Current EBITDA COMPUTED$3.9M
Operating Margin COMPUTED8.4%
Occupancy HCRIS12.3%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS41.4%
Distress Probability ML56.6%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
72
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of 8.4% places it above the state median. Among 72 size-comparable peers (12-50 beds), the median margin is -3.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 72 hospitals in the comp set.

HospitalStateBedsRevenueMargin
MYMICHIGAN MEDICAL CENTER GLAD (Target)MI25$45.8M8.4%
TRINITY HEALTH LIVINGSTONMI42$200.4M15.2%
MYMICHIGAN MEDICAL CENTER ALMAMI49$142.2M-5.9%
SPECTRUM HEALTH UNITED MEMORIAMI45$129.4M9.7%
DICKINSON COUNTY HEALTHCARE SYMI49$126.3M-4.7%
MUNSON HEALTHCARE CADILLAC HOSMI49$122.7M1.0%
MCLAREN CENTRAL MICHIGANMI49$118.9M-35.3%
SPECTRUM HEALTH GERBERMI25$116.2M16.0%
SPECTRUM HEALTH LUDINGTONMI45$110.1M5.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$961K+210bp18mo
Cost to Collect4.5%2.5%$915K+200bp12mo
Denial Rate Reduction12.0%6.5%$906K+198bp12mo
A/R Days Reduction5200.0%3800.0%$557K+122bp9mo
Clean Claim Rate88.0%96.0%$29K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$961K
Cost to Collect
$915K
Denial Rate Reduction
$906K
A/R Days Reduction
$557K
Clean Claim Rate
$29K
Total EBITDA Uplift$3.4M
Current EBITDA$3.9M
+ RCM Uplift+$3.4M
Pro Forma EBITDA$7.2M
Current Margin8.4%
Pro Forma Margin15.8%
WC Released (1x)$1.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$5.9M$59.1M9.96x58.4%
Base (11x exit)10.0x11.0x$5.9M$67.0M11.28x62.4%
Bull Case9.0x11.0x$5.3M$80.0M14.98x71.8%
Bull (12x exit)9.0x12.0x$5.3M$88.9M16.64x75.5%
Bear Case11.0x10.0x$6.5M$40.4M6.18x44.0%
Bear (11x exit)11.0x11.0x$6.5M$46.5M7.13x48.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 12.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 56.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 72 hospitals with 12-50 beds
  • Same-state prioritization (n=73)
  • Comp margins: P25=-11.8% / P50=-3.5% / P75=7.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.